BYON-3521

N/A

Report date: 2024/11/29 20:00:39

Base Information

Drug NameBYON-3521

Drug Alias NameBYON-3521

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > seco-DUBA payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionAlkylating agentsDNA synthesis inhibitorsAnti-Hepatocyte growth factor receptor

TargetsHepatocyte growth factor receptor

Therapy Area/IndicationsSolid tumoursNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumNetherlandsItaly +[4]

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesByondis Bv

China Registration ClassN/A

Develop Information

Active CompaniesByondis Bv

Inactive CompaniesN/A

Active IndicationsSolid tumoursNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A